Current trends in diabetic retinopathy
DOI:
https://doi.org/10.5281/zenodo.13748547%20Keywords:
angiogenesis inhibitors, diabetic retinopathy, light coagulationAbstract
Introduction: diabetic retinopathy is a microangiopathic disease, characterized by loss of pericytes and thickening of the basement membrane, secondary to prolonged hyperglycemia and associated with genetic factors. A worldwide prevalence of 40 % and an incidence of 90 % after 30 years, and 50 % at 10 years of suffering from diabetes are estimated. This condition causes 8 % blindness cases among diabetic patients, and is its first cause after 65 years of age.
Objective: to present current trends in the diagnosis and treatment of diabetic retinopathy.
Methods: the articles published on this topic in the PubMed, SciELO, Cumed, ClinicalKey, LILACS, EBSCO databases and in the Google Scholar search engine were reviewed. Works published during the last five years, in English and Spanish, were selected.
Development: the pathophysiological alterations of diabetic retinopathy are hematological and biochemical. They include platelet adhesiveness, increased erythrocyte aggregation, lipid abnormalities, fibrinolysis defects, abnormal growth hormone concentrations, vascular endothelial growth factor activation, as well as alterations in serum viscosity. Current treatment is mainly based on glycemic control, panretinal photocoagulation with diffuse pattern or grid yellow-green light pars plana vitrectomy, and anti-vascular endothelial growth factor drugs, depending on the stage of the disease.
Conclusions: the application of new trends in the diagnosis and treatment of this disease will allow a better expectation and quality of life for patientsDownloads
References
Hammes HP. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia [Internet]. 2018 [citado 12 Ago 2020];61(1):29-38. Disponible en: https://link.springer.com/content/pdf/10.1007/s00125-017-4435-8.pdf
Abdel-Maksoud SM, Hassanein SI, Gohar NA, Attia SMM, Gad MZ. Investigation of brainderived neurotrophic factor (BDNF) gene expression in hypothalamus of obese rats: modulation by omega-3 fatty acids. Nutr Neurosci [Internet]. Oct 2017 [citado 12 Ago 2020];20(8):443-8. Disponible en: https://www.researchgate.net/profile/Mohamed-Gad-33/publication/301820745_Investigation_of_brain_derived_neurotrophic_factor_BDNF_gene_expression_in_hypothalamus_of_obese_rats_Modulation_by_omega_3_fatty_acids/data/5c9102ae299bf14e7e8670b4/Gad-BDNF.pdf
Ohba M, Saeki K, Koga T, Okuno T, Kobayashi Y, Yokomizo T. Profiling of bioactive lipids in different dendritic cell subsets using an improved multiplex quantitative LC-MS/MS method. Biochem Biophys Res Commun [Internet]. Oct 2018 [citado 12 Ago 2020];504(3):562-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29890138/
Hirakata T, Lee HC, Ohba M, Saeki K, Okuno T, Murakami A, et al. Dietary ω-3 fatty acids alter the lipid mediator profile and alleviate allergic conjunctivitis without modulating Th2 immune responses. FASEB J [Internet]. Mar 2019 [citado 12 Ago 2020];33(3):3392-403. Disponible en: https://faseb.onlinelibrary.wiley.com/doi/epdf/10.1096/fj.201801805R
Dong Y, Pu KJ, Duan WJ, Chen HC, Chen LX, Wang YM. Involvement of Akt/CREB signaling pathways in the protective effect of EPA against interleukin-1β-induced cytotoxicity and BDNF down-regulation in cultured rat hippocampal neurons. BMC Neurosci [Internet]. Sep 2018 [citado 12 Ago 2020];19(1): Disponible en: https://bmcneurosci.biomedcentral.com/track/pdf/10.1186/s12868-018-0455-7.pdf
Ghanchi F. The Royal College of Otphalmologist clinical guidelines for diabetic retinopathy:a summary. Eye 2013;27:285-7. [Internet]. Sep 2018 [citado 12 Ago 2020];19(1): Disponible en: https://doi.org/10.1038/eye.2012.287.
Royle P, Mistry H, Auguste P, Shyangdan D, Freeman K, Lois N, et al. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Health Technol Assess [Internet]. Jul 2015 [citado 12 Ago 2020];19(51):v-xxviii. Disponible en: https://njl-admin.nihr.ac.uk/document/download/2002737
International Diabetes Federation. Atlas de la diabetes de la FID [Internet]. 9na ed. Bruselas: IDF; 2019 [citado 12 Ago 2020]. Disponible en: https://diabetesatlas.org/upload/resources/material/20200302_133352_2406-IDF-ATLAS-SPAN-BOOK.pdf
The Lancet. Type 2 diabetes: the urgent need to protect young people. Lancet [Internet]. Dic 2018 [citado 12 Ago 2020];392(10162):2325. Disponible en: https://www.thelancet.com/action/showPdf?pii=S0140-6736%2818%2933015-0
Stehouwer CDA. Microvascular dysfunction and hyperglycemia: a vicious cycle with widespread consequences. Diabetes [Internet]. Sep 2018 [citado 12 Ago 2020];67(9):1729-41. Disponible en: https://diabetes.diabetesjournals.org/content/diabetes/67/9/1729.full.pdf
Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol [Internet]. 2018 [citado 12 Ago 2020];136(10):1138-48. Disponible en: https://jamanetwork.com/journals/ophth/articlepdf/2688792/jamaophthalmology_gross_2018_oi_180062.pdf
Lau PE, Jenkins KS, Layton CJ. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. J Ophthalmol [Internet]. 2018 [citado 12 Ago 2020];2018:8567912. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098904/pdf/JOPH2018-8567912.pdf
Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient’s perspective. Clin Ophthalmol. [Internet]. 2018 [citado 12 Ago 2020];12:2483-91. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287411/pdf/opth-12-2483.pdf
Fong DS, Ferris FL III, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Am J Ophthalmol [Internet]. Feb 1999 [citado 12 Ago 2020];127(2):137-41. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0002939498003092?via%3Dihub
Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health [Internet]. Feb 2014 [citado 12 Ago 2020];2(2):106-16. Disponible en: https://www.sciencedirect.com/science/article/pii/S2214109X13701451/pdfft?md5=a57fe87741199a6ccf0975f4d4fa2743&pid=1-s2.0-S2214109X13701451-main.pdf
Maguire MG, Liu D, Glassman AR, Jampol LM, Johnson CA, Baker CW, et al. Visual field changes over 5 years in patients treated with panretinal photocoagulation or ranibizumab for proliferative diabetic retinopathy. JAMA Ophthalmol [Internet]. 2020 [citado 12 Ago 2020];138(3):285-93. Disponible en: https://jamanetwork.com/journals/ophth/articlepdf/2759805/jamaophthalmology_maguire_2020_oi_190098.pdf
Seah I, Zhao X, Lin Q, Liu Z, Su SZZ, Yuen YS, et al. Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. Eye (Lond) [Internet]. 2020 [citado 12 Ago 2020];34(8):1341-56. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376230/pdf/41433_2020_Article_770.pdf
Tsujinaka H, Fu J, Shen J, Yu Y, Hafiz Z, Kays J, et al. Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles. Nat. Commun [Internet]. 2020 [citado 12 Ago 2020];11(1):694-707. Disponible en: https://www.nature.com/articles/s41467-020-14340-x.pdf
Suzumura A, Kaneko H, Funahasi Y, Takayama K, Nayaga M, Ito S, et al. Omega-3 fatty acid and its metabolite 18-HEPE ameliorate retinal neuronal cell dysfunction by enhancing Müller BDNF in diabetic retinopathy. Diabetes [Internet]. Abr 2020 [citado 12 Ago 2020];69(4):724-35. Disponible en: https://diabetes.diabetesjournals.org/content/diabetes/69/4/724.full.pdf
Fernández-Albarral JA, De Hoz R, Ramírez AI, López-Cuenca I, Salobrar-García E, Pinazo-Durán MD, et al. Beneficial effects of saffron (Crocus sativus L.) in ocular pathologies, particularly neurodegenerative retinal diseases. Neural Regen Res [Internet]. Ago 2020 [citado 12 Ago 2020];15(8):1408-16. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059587/pdf/NRR-15-1408.pdf
Ikeda HO, Muraoka Y, Hata M, Sumi E, Ikeda T, Nakagawa T, et al. Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: an open-label, non-randomized, first-in-humans, phase 1/2 trial. PLoS One [Internet]. 2020 [citado 12 Ago 2020];15(2):e229068. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018138/pdf/pone.0229068.pdf
Preguiça I, Alves A, Nunes S, Gomes P, Fernandes R, Viana SD, et al. Diet-induced rodent models of diabetic peripheral neuropathy, retinopathy and nephropathy. Nutrients [Internet]. 2020 [citado 12 Ago 2020];12(1):[aprox 18 p.]. Disponible en: https://www.mdpi.com/2072-6643/12/1/250/pdf
Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology [Internet]. Oct 2006 [citado 12 Ago 2020];113(10):1695-1705.e6. Disponible en: https://www.academia.edu/download/48197136/j.ophtha.2006.05.06420160820-30877-tte97r.pdf
Eguía-Martínez F, Río-Torres M, Capote-Cabrera A, Ríos-Caso R, Hernández-Silva JR, Gómez-Cabrera CG, et al. Manual de diagnóstico y tratamiento en oftalmología [Internet]. La Habana: Editorial Ciencias Médicas; 2009 [citado 12 Ago 2020]. Disponible en: http://www.bvs.sld.cu/libros/manual_diag_ttmo_oftalmologia/manual_diag_ttmo_oftal_completo.pdf
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Carmen Castillo Vázquez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
